Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Extension Protocol for Extended Use of OncoVEX^GM-CSF for Eligible Patients Participating in Study 002/03: Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma

NCT02574260 is registered in ClinicalTrials.gov with BioVex Limited as lead sponsor.

NCT NCT02574260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02574260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Extension Protocol for Extended Use of OncoVEX^GM-CSF for Eligible Patients Participating in Study 002/03: Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Lead sponsor
BioVex Limited
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
January 31, 2010
Enrollment
3 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma